Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › neuroblastoma

Neuroblastoma

Part of Germ cell tumors

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for neuroblastoma

44 trials tracked for neuroblastoma: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 254 citations.

44Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 29 Phase 1 6 Other / NA 7
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 254 cited
  2. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 126 cited
  3. Phase 2 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed
  4. Phase 2 N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma Completed
  5. Phase 2 ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Completed
  6. Phase 2 Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission Completed
Show 38 more trials
  1. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  2. Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma Completed
  3. Phase 2 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma Completed
  4. Phase 2 Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed
  5. Phase 2 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Completed
  6. Phase 2 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed
  7. Phase 2 Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma Completed
  8. Phase 2 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma Completed
  9. Phase 2 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed
  10. Phase 2 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation Completed
  11. Phase 2 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma Completed
  12. Phase 2 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Completed
  13. Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
  14. Phase 2 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Completed
  15. Phase 2 Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT Completed
  16. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  17. Phase 2 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed
  18. Phase 2 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Completed
  19. Phase 2 Oral Liquid 13-cis-retinoic Acid (13-CRA) Completed
  20. Phase 2 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Completed
  21. Phase 2 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow Completed
  22. Phase 2 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed
  23. Phase 2 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer Completed
  24. Phase 2 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Completed
  25. Phase 2 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Completed
  26. Phase 1 Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide Completed
  27. Phase 1 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Completed
  28. Phase 1 MIBG With Dinutuximab +/- Vorinostat Completed
  29. Phase 1 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma Completed
  30. Phase 1 High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma Completed
  31. Phase 1 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma Completed
  32. N/A Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Completed
  33. N/A Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma Completed
  34. N/A Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma Completed
  35. N/A Molecular-Guided Therapy for Childhood Cancer Completed
  36. N/A Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients Completed
  37. N/A High-Risk Neuroblastoma Chemotherapy Without G-CSF Completed
  38. N/A Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma
Pediatrics Phase II
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma New Antibody Boosts Survival in High-Risk Neuroblastoma
This Phase II pilot study enrolled 153 previously untreated children with high-risk neuroblastoma. The study assessed hu14.18K322A combined …
This study shows that combining a new antibody with standard chemotherapy may improve survival rates for children with high-risk neuroblasto…
CT.gov Jun 4, 2026
Review examines multi-omics approaches to enhance diagnostic precision and treatment decisions in pediatric neuroblastoma
Pediatrics Sys. Review
Review examines multi-omics approaches to enhance diagnostic precision and treatment decisions in pediatric neuroblastoma The AI Tool That's Changing How Doctors Fight Childhood Cancer
This narrative review evaluates the application of multi-omics approaches, including transcriptomics and radiomics, for children with neurob…
A new AI tool combines genetic tests and imaging to help doctors diagnose and treat unpredictable childhood cancer called neuroblastoma more…
Frontiers Apr 18, 2026